Danaher Announces Leadership Transition in China Diagnostics Platform Amid Strategic IPO Filing

1Month13On [Date], Danaher Group officially announced important personnel changes in the China Diagnostic Platform:Chen Xiaosui (Rosa）will step down as President of China Diagnostic Platform, and Yu Jing, former Vice President of Medtronic and General Manager of China Orthopedics and Neurosurgery Business, has officially taken over.。

Chen Xiaosui at2021Year9Joined Danaher in the month, serving as Vice President and General Manager of Beckman Coulter Clinical Diagnostics China, and later as President of Danaher China Diagnostic Platform, during which time he promoted localization breakthroughs and policy adaptation for the diagnostics business.

According to publicly available information, under his leadership, Beckman Coulter became the first foreign-funded company to complete the localization of high-end production lines in China.IVDEnterprises, Reagent Localization Accelerates Simultaneously, Platform80%The above diagnostic instruments have achieved local production in China. Facing multiple rounds of volume-based procurement (VBP) Policy challenges, Chen Xiaosui led the team to establish a dynamic response mechanism, and in the historically largest procurement of tumor markers and thyroid function tests led by Anhui, they expanded market share against the trend, becoming the only leading foreign enterprise among the "Big Four" to successfully defend its position in multiple rounds of biochemical and immunoassay procurements. Internally, Danaher evaluated that she has "made significant and lasting contributions to the diagnostics business," especially in organizational restructuring.DBSDemonstrates exceptional leadership in system advancement and local innovation collaboration.

Yu Jing, the successor, has cross-industry and cross-field compound experience. SheGEMedical Group Super20Year, starting as a global procurement manager, and having served in roles such as Director of Clinical Systems Operations for the Asia-Pacific region, General Manager of the China Ultrasound Division, and Sales General Manager of the Non-Public Healthcare and Basic Healthcare Business Unit, leading over...1200People team, management scale reaches20Billion US dollars. 

2019After joining Medtronic in [Year], Jing Yu served as the General Manager of China Orthopedics and Neurosurgery business, leading the advancement of the digital and intelligent transformation strategy: developmentAIBLEIntegrated Solution for Digital and Intelligent Orthopedics and Neurosurgery, incorporating surgical robots, navigation systems, intraoperative imaging, and other smart equipment.AIData platform, promoting equipment interconnection and data interoperability; participating in the construction of the Changzhou Science Park Innovation Incubation Center, fostering local R&D and global resource integration;2025During the CIIE, its leadingAiBLEThe ecological family of products has completed commercialization, achieving a leap from "exhibition stand" to "operating table."

Medtronic's announcement shows that Jing Yu left due to personal development reasons.2025Year11Left in the month, the innovative achievements he promoted, such as "Robot-guided laser ablation minimally invasive technology," have realized the deep integration of global intelligence and Chinese innovation.

END